Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Tenalisib

ed072d8f-390a-578d-b8e4-f35f7365db72 · FDA Phase I Trials Completed · targets PI3K

Tenalisib

MeasuredReference

Tenalisib targets RET, NTRK3, FGFR3. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

RETNTRK3FGFR3JAK1FGFR2

Top hallmarks

  • tumor promoting inflammation3.2k
  • proliferation2.0k
  • immune evasion1.8k

Top pathways disrupted

No pathway data.

Resistance landscape — Tenalisib

MeasuredReference

10 known oncogenic variants exist on Tenalisib's top targets — see detail for inhibition impact.

Open in new tab